Pharmaceutical patents need a new lease of life

Patrick Duxbury and Emma Tuck ask whether the increasing cost of drug development, and the declining numbers of drugs being approved, mean that IP protection for life science products should be reevaluated.

Patent pools in the pharmaceutical industry – sink or swim?

Patent pools as a tool for the collective management of intellectual property rights are not a new concept.

Patent misuse in the pharmaceutical industry: developments in US & EU

The pharmaceutical industry has been scrutinized closely by competition authorities and Courts in the US and Europe.